Harold Keer

Corporate Officer/Principal at Stanford University

Health Technology

Consumer Services

Harold Keer active positions

Companies	Position	Start	End
Stanford University	Corporate Officer/Principal	-	-

Companies	Position	Start	End
EXELIXIS, INC.	Chief Tech/Sci/R&D Officer	06/07/2011	-
EXELIXIS, INC.	Corporate Officer/Principal	-	06/07/2011
TITAN PHARMACEUTICALS, INC.	Corporate Officer/Principal	-	-
FIVE PRIME THERAPEUTICS, INC.	Chief Tech/Sci/R&D Officer	06/07/2011	-
FIVE PRIME THERAPEUTICS, INC.	Corporate Officer/Principal	-	06/07/2011

Northwestern University

Doctorate Degree

International

United States

Operational

Corporate Officer/Principal	4
Chief Tech/Sci/R&D Officer	2
Doctorate Degree	1

Sectoral

Health Technology	4
Consumer Services	3

Positions held

Active

Inactive

Listed companies

Private companies

Listed companies	2
EXELIXIS, INC.	Health Technology
TITAN PHARMACEUTICALS, INC.	Health Technology

Private companies	1
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C.	Health Technology

Private companies

Health Technology